End-of-day quote
Korea S.E.
03:30:00 04/07/2024 am IST
|
5-day change
|
1st Jan Change
|
13,580
KRW
|
-2.30%
|
|
+22.90%
|
+48.25%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
70,067
|
76,165
|
1,23,061
|
93,238
|
88,582
|
1,01,553
|
Enterprise Value (EV)
1 |
48,995
|
52,328
|
58,516
|
40,899
|
24,595
|
59,819
|
P/E ratio
|
11.3
x
|
13.3
x
|
21.1
x
|
13.6
x
|
10.1
x
|
24
x
|
Yield
|
0.79%
|
0.73%
|
0.45%
|
0.59%
|
0.63%
|
0.55%
|
Capitalization / Revenue
|
0.98
x
|
1.1
x
|
1.61
x
|
1.12
x
|
0.95
x
|
1.16
x
|
EV / Revenue
|
0.68
x
|
0.75
x
|
0.77
x
|
0.49
x
|
0.26
x
|
0.68
x
|
EV / EBITDA
|
5.07
x
|
5.4
x
|
5.46
x
|
3.24
x
|
2.18
x
|
8.31
x
|
EV / FCF
|
18.2
x
|
-13.3
x
|
7.76
x
|
-122
x
|
-13.8
x
|
-12.9
x
|
FCF Yield
|
5.5%
|
-7.53%
|
12.9%
|
-0.82%
|
-7.25%
|
-7.77%
|
Price to Book
|
0.94
x
|
0.94
x
|
1.18
x
|
0.84
x
|
0.75
x
|
0.83
x
|
Nbr of stocks (in thousands)
|
11,087
|
11,087
|
11,087
|
11,087
|
11,087
|
11,087
|
Reference price
2 |
6,320
|
6,870
|
11,100
|
8,410
|
7,990
|
9,160
|
Announcement Date
|
21/03/19
|
18/03/20
|
22/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
71,823
|
69,537
|
76,255
|
82,957
|
93,504
|
87,622
|
EBITDA
1 |
9,666
|
9,689
|
10,717
|
12,623
|
11,289
|
7,199
|
EBIT
1 |
7,923
|
7,352
|
8,122
|
9,685
|
8,174
|
3,801
|
Operating Margin
|
11.03%
|
10.57%
|
10.65%
|
11.68%
|
8.74%
|
4.34%
|
Earnings before Tax (EBT)
1 |
8,046
|
7,733
|
8,679
|
12,195
|
10,713
|
6,305
|
Net income
1 |
6,223
|
5,727
|
5,821
|
6,789
|
8,628
|
4,182
|
Net margin
|
8.66%
|
8.24%
|
7.63%
|
8.18%
|
9.23%
|
4.77%
|
EPS
2 |
561.3
|
516.5
|
526.0
|
619.0
|
788.0
|
382.0
|
Free Cash Flow
1 |
2,696
|
-3,940
|
7,538
|
-335.4
|
-1,784
|
-4,645
|
FCF margin
|
3.75%
|
-5.67%
|
9.89%
|
-0.4%
|
-1.91%
|
-5.3%
|
FCF Conversion (EBITDA)
|
27.89%
|
-
|
70.34%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
43.32%
|
-
|
129.5%
|
-
|
-
|
-
|
Dividend per Share
2 |
50.00
|
50.00
|
50.00
|
50.00
|
50.00
|
50.00
|
Announcement Date
|
21/03/19
|
18/03/20
|
22/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
21,072
|
23,837
|
64,545
|
52,339
|
63,987
|
41,734
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2,696
|
-3,940
|
7,538
|
-335
|
-1,784
|
-4,645
|
ROE (net income / shareholders' equity)
|
9.02%
|
7.75%
|
6.93%
|
7.55%
|
8.25%
|
4.1%
|
ROA (Net income/ Total Assets)
|
5.92%
|
4.86%
|
4.03%
|
3.87%
|
2.92%
|
1.25%
|
Assets
1 |
1,05,173
|
1,17,806
|
1,44,433
|
1,75,531
|
2,95,003
|
3,35,459
|
Book Value Per Share
2 |
6,731
|
7,289
|
9,423
|
9,993
|
10,701
|
11,027
|
Cash Flow per Share
2 |
836.0
|
1,057
|
909.0
|
560.0
|
655.0
|
1,295
|
Capex
1 |
3,596
|
7,163
|
8,570
|
6,321
|
5,532
|
9,422
|
Capex / Sales
|
5.01%
|
10.3%
|
11.24%
|
7.62%
|
5.92%
|
10.75%
|
Announcement Date
|
21/03/19
|
18/03/20
|
22/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +48.25% | 11Cr | | +54.07% | 81TCr | | +39.81% | 62TCr | | -7.05% | 35TCr | | +15.44% | 32TCr | | +5.72% | 29TCr | | +14.37% | 24TCr | | +0.74% | 22TCr | | +14.69% | 22TCr | | +7.42% | 17TCr |
Other Pharmaceuticals
|